Welcome to our dedicated page for Profusa news (Ticker: PFSA), a resource for investors and traders seeking the latest updates and insights on Profusa stock.
Profusa, Inc. (Nasdaq: PFSA) is a commercial stage digital health and medical technology company based in Berkeley, California, focused on tissue-integrated biosensors and its Lumee Oxygen tissue monitoring platform. The Profusa news feed on this page aggregates company press releases and third-party coverage related to its technology, clinical studies, commercial partnerships and capital markets activity.
Readers can expect technology and clinical news about Lumee Oxygen tissue monitoring, including study results in peripheral artery disease (PAD) and critical limb threatening ischemia (CLTI). Profusa has reported pilot phase data from a U.S.-based clinical study showing that Lumee oxygen traces strongly correlated with transcutaneous partial pressure of oxygen and that sensors remained functional for up to one year without sensor placement-related adverse events. News items also cover presentations at major vascular conferences such as Paris Vascular Insights and the Leipzig Interventional Course (LINC), where Profusa discusses additional insights into tissue oxygen monitoring.
The PFSA news stream also highlights commercial and distribution developments. Profusa has announced distributor partnerships in European markets for Lumee Oxygen tissue monitoring, including agreements intended to cover significant portions of the European Union population and to serve hospital and outpatient wound care settings. Additional releases describe collaborations with leading vascular surgeons and vascular centers in France and Greece, where Lumee technology is being adopted in clinical practice and clinical studies.
Investors will find corporate and financing updates in Profusa’s news, including details on its business combination with NorthView Acquisition Corporation, recapitalization efforts, senior secured convertible notes, and equity line of credit arrangements. The company has also outlined its own revenue targets and commercialization timelines in press releases, along with manufacturing milestones such as completion of sensor production runs and engagement of contract manufacturers for Lumee components.
By following this PFSA news page, users can track how Profusa communicates progress on its Lumee Oxygen platform, clinical validation, European commercialization plans, and balance sheet restructuring, as disclosed through its public announcements.
Profusa (NASDAQ:PFSA), a commercial stage digital health company, has completed its business combination with NorthView Acquisition Corp (NVAC). The company's common stock will begin trading on Nasdaq under the ticker "PFSA" on July 14, 2025.
The combined company secured $9 million through a secured convertible promissory note from an institutional investor, with potential access to up to $20 million under the convertible note facility. The funds will support transaction costs and working capital needs.
Profusa specializes in tissue-integrating biosensors that can monitor body chemistry continuously, transmitting data to smartphone applications and utilizing AI technologies for health management, particularly focusing on conditions like diabetes, critical limb ischemia, and peripheral arterial disease.